Endpoints News |
Axovant's lead Alzheimer's drug flops in PhIII, ending an unlikely quest
Endpoints News Vivek Ramaswamy burst onto the biotech scene a few years ago with a brash plan to grab a failed Alzheimer's drug from GlaxoSmithKline and hustle it straight into a pivotal Phase III study for Alzheimer's — a disease that has defeated every pivotal ... Despite hope and hype, Axovant serves up another failed Alzheimer's med Axovant Announces Negative Topline Results of Intepirdine Phase 3 MINDSET Trial in Alzheimer's Disease Opinion The link between SoftBank, Alzheimer's and data |
from Health - Google News http://ift.tt/2xIniTt
EmoticonEmoticon